Compare CPB & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPB | BLCO |
|---|---|---|
| Founded | 1869 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Ophthalmic Goods |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.4B |
| IPO Year | 1994 | 2022 |
| Metric | CPB | BLCO |
|---|---|---|
| Price | $22.03 | $16.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 11 |
| Target Price | ★ $26.06 | $18.45 |
| AVG Volume (30 Days) | ★ 10.2M | 344.9K |
| Earning Date | 06-01-2026 | 04-29-2026 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | ★ 6.35 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $10,253,000,000.00 | $5,101,000,000.00 |
| Revenue This Year | N/A | $8.65 |
| Revenue Next Year | $0.11 | $5.59 |
| P/E Ratio | $13.85 | ★ N/A |
| Revenue Growth | 6.40 | ★ 6.47 |
| 52 Week Low | $19.56 | $13.09 |
| 52 Week High | $34.18 | $18.92 |
| Indicator | CPB | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 51.33 |
| Support Level | $20.16 | $15.36 |
| Resistance Level | $22.85 | $16.54 |
| Average True Range (ATR) | 0.79 | 0.48 |
| MACD | -0.10 | 0.07 |
| Stochastic Oscillator | 49.53 | 52.59 |
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.